TLDR
- SELLAS Life Sciences (SLS) stock is up 255% year-to-date as traders position ahead of Phase 3 REGAL trial data for cancer drug galinpepimut-S in acute myeloid leukemia
- The trial has hit the 80-event threshold required to trigger final analysis
- A new Haematologica study suggests current standard treatments may be less effective than thought, potentially benefiting SELLAS’s drug
- Institutional ownership is rising, with Quantinno Capital Management taking a new $315,000 position in Q1
- Analyst consensus sits at “Hold” with a price target of $10.00, well below the current trading price of $15.46
SELLAS Life Sciences (SLS) stock opened at $15.46 on Monday, near its 52-week high of $15.88, after a year-to-date run of over 255%. The stock has a 52-week low of $1.39, which shows just how much ground it has covered in a short time.
SELLAS Life Sciences Group, Inc., SLS
The catalyst driving recent momentum is the Phase 3 REGAL trial for galinpepimut-S, SELLAS’s cancer drug targeting acute myeloid leukemia. The trial has now reached the 80-event threshold needed to trigger its final data analysis. That milestone is putting the stock on traders’ radars.
Adding fuel to the move, a newly published study in Haematologica suggests that existing standard-of-care treatments for the disease may be less effective than previously thought. If that holds up, it could lower the bar galinpepimut-S needs to clear to stand out in the competitive leukemia space.
Institutional investors have been quietly adding exposure. Quantinno Capital Management LP picked up 74,378 shares in Q1, valued at around $315,000. Other recent buyers include Larson Financial Group, BNP Paribas Financial Markets, Concurrent Investment Advisors, and Beacon Pointe Advisors.
Collectively, institutions now own 17.38% of the company. That is not a huge number, but the direction of travel matters here.
Analyst Ratings and Price Targets
Despite the stock’s run, analyst sentiment is mixed. Alliance Global Partners has a Buy rating, reaffirmed on August 12th. Weiss Ratings is on the other end, maintaining a Sell (D-) rating. That leaves the consensus at “Hold” with a price target of $10.00, roughly 35% below where the stock is currently trading.
SLS has a market cap of $3.12 billion, a PE ratio of -73.62, and a beta of 2.48. That beta number tells you a lot. This stock moves fast and hard in both directions.
Financials and Risk Factors
On the balance sheet side, SELLAS carries a low debt load and has improved its cash position, giving it more runway to fund clinical programs. The 50-day moving average sits at $11.85 and the 200-day at $7.75, both well below the current price.
But there are real risks here. The company has no commercial revenue, is burning cash, and continues to issue new stock to raise funds. An adverse arbitration ruling adds to the uncertainty. The quarterly EPS came in at -$0.05, missing estimates of -$0.04 by a penny.
Everything hinges on what the REGAL trial data shows. The stock’s current valuation is entirely forward-looking. At $15.46, the market is pricing in a lot of good news that has not been confirmed yet.
The consensus price target of $10.00 remains well below the current stock price.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
